$NVCR News
Last published 2d ago
- 2d agoNVCRNovocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung CancerBusiness WireBAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune Mya® for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. The Not Approvable Letter indicate ...
- 1w agoNVCRNovocure Q3 2026 Earnings - NOVOCURE LTDEarnings Call TranscriptsGood day and welcome to the NovoCure Q3 2026 earnings call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question, you wi
- 1w agoNVCRNovoCure Ltd - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoNVCRNovocure Reports Third Quarter 2026 Financial Results and Raises 2026 GuidanceBusiness WireThird quarter net revenues of $193 million an increase of 16% year-over-year, driven by 19% growth in active patients worldwide Strong performance drove increased net revenue guidance for full-year 2026 to $736
- 1mo agoNVCRNovocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic CancerBusiness WireNovocure (NASDAQ:NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer,
- 1mo agoNVCRNovocure to Report Third Quarter 2026 Financial ResultsBusiness WireNovocure (NASDAQ:NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m.
- 1mo agoNVCRMorgan Stanley 24th Annual Global Healthcare Conference - NOVOCURE LTDEarnings Call TranscriptsGood afternoon, everyone. I'm very happy to be here on the first day of the Morgan Stanley Healthcare Conference, joined by the management team of NovoCure. I am sitting here with CEO Frank Leonard and CFO Christoph Brac
- 1mo agoNVCRMorgan Stanley 24th Annual Global Healthcare Conference - NOVOCURE LTDEarnings Call TranscriptsGood afternoon, everyone. I'm very happy to be here on the first day of the Morgan Stanley Healthcare Conference, joined by the management team of NovoCure. I am sitting here with CEO Frank Leonard and CFO Christoph Brac
- 2mo agoNVCRWells Fargo 21st Annual Healthcare Conference - NOVOCURE LTDEarnings Call TranscriptsGood morning, everyone. My name is Lei Huang with the Wells Fargo MedTech Research Team. Welcome. I'm pleased to have with us Novacure. And from the company is CEO Frank Leonard. Thank you, Frank, for joining us. Thanks,
- 2mo agoNVCRWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - NOVOCURE LTDEarnings Call TranscriptsGood morning, everyone. My name is Lei Huang with the Wells Fargo MedTech Research Team. Welcome. I'm pleased to have with us Novacure. And from the company is CEO Frank Leonard. Thank you, Frank, for joining us. Thanks,
- 2mo agoNVCRNovocure Announces Upcoming Investor EventsBusiness WireNovocure (NASDAQ:NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonard, Chief Executive Officer, will
- 3mo agoNVCRNovocure Q2 2026 Earnings - NOVOCURE LTDEarnings Call TranscriptsGood day and welcome to Novacure's second quarter 2026 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a ques
- 3mo agoNVCRNovocure Reports Second Quarter 2026 Financial ResultsBusiness WireQuarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications CE Mark received for Optune Pax® for the treatment of locally advanced
- 4mo agoNVCRNovocure to Report Second Quarter 2026 Financial ResultsBusiness WireNovocure (NASDAQ:NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT,
- 4mo agoNVCRNovocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic CancerBusiness WireThe CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with gemcitabine and
- 4mo agoNVCRNovocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)PR NewswireInvestors who held Novocure Limited (NASDAQ: NVCR) shares lost more than $3 per share on June 18, 2026, when the stock had fallen over 18% in a...
- 4mo agoNVCRNovocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed GlioblastomaBusiness WireThe Phase 3 TRIDENT trial enrolled patients with glioblastoma prior to the initiation of chemoradiation and evaluated the benefit of initiating Tumor Treating Fields (TTFields) therapy at the start of chemoradiation
- 6mo agoNVCRNovocure Reports First Quarter 2026 Financial ResultsBusiness WireQuarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic
- 7mo agoNVCRNovocure to Report First Quarter 2026 Financial ResultsBusiness WireNovocure (NASDAQ:NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT,
- 7mo agoNVCRNovocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic CancerBusiness WireNovocure (NASDAQ:NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq®), gemcitabine and nab-paclitaxel
- 8mo agoNVCRNovocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung CancerBusiness WireNovocure to launch Optune Lua in Japan with national reimbursement coverage Novocure (NASDAQ:NVCR) announced today that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua®
- 8mo agoNVCRNovocure to Participate in 2026 Leerink Global Healthcare ConferenceBusiness WireNovocure (NASDAQ:NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph Brackmann, Chief
- 8mo agoNVCRNovocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company UpdateBusiness WireFull year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Optune Pax® approved by the U.S. FDA for the treatment of locally advanced pancreatic cancer, commercial launch
- 8mo agoONCYIBRXCRSPBNTX+1Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026PR NewswireEquity Insider News Commentary, The immuno-oncology market is forecast to grow from $65.22 billion in 2025 to $170.19 billion by 2032, fueled by...
- 8mo agoNVCRTumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)Business WireBritish Columbia becomes first Canadian province to provide coverage for TTFields therapy for eligible glioblastoma patients Novocure (NASDAQ:NVCR) announced today that the province of British Columbia, Canada, will
- 8mo agoONCYNVCRCATXIBRX+1New Treatment Modalities Are Reaching Cancers That Resisted Everything ElsePR NewswireEquity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing...
- 8mo agoONCYNVCRCATXIBRX+1New Treatment Modalities Are Reaching Cancers That Resisted Everything ElsePR NewswireEquity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing...
- 9mo agoNVCRU.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic CancerBusiness WireOptune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3 PANOVA-3 trial showed a statistically significant
- 10mo agoNVCRNovocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company UpdateBusiness WirePreliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Novocure to present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PST on Wednesday, January
- 10mo agoNVCRNovocure to Present at 44th Annual J.P. Morgan Healthcare ConferenceBusiness WireNovocure (NASDAQ:NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank Leonard, Chief Executive Officer,
- 11mo agoNVCRNovocure Appoints Company President Frank Leonard as Chief Executive OfficerBusiness WireNovocure (NASDAQ:NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has
- 11mo agoNVCRNovocure to Participate in 37th Annual Piper Sandler Healthcare ConferenceBusiness WireNovocure (NASDAQ:NVCR) announced today that management will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle, Novocure's Executive Chairman, will
- 12mo agoNVCRNovocure to Participate in 2025 Jefferies Global Healthcare ConferenceBusiness WireNovocure (NASDAQ:NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer, will present on
- 1y agoNVCRNovocure Reports Third Quarter 2025 Financial ResultsBusiness WireQuarterly net revenues of $167 million, up 8% year-over-year, with 4,416 active patients on therapy as of September 30, 2025 Premarket approval application for Tumor Treating Fields therapy use in pancreatic cancer
- 1y agoNVCRNovocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) CongressBusiness WireNovocure (NASDAQ:NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in Prague, Czech Republic,
- 1y agoNVCRNovocure to Report Third Quarter 2025 Financial ResultsBusiness WireNovocure (NASDAQ:NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m.
- 1y agoNVCRNovocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual MeetingBusiness WireMETIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial progression in patients receiving TTFields therapy and best supportive care following stereotactic radiation of the metastases
- 1y agoNVCRNovocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)Business WireOptune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy Ministry of Health, Labour
- 1y agoNVCRNovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Earnings Call Transcripts
- 1y agoNVCRNovocure Announces Upcoming Investor EventsBusiness WireNovocure (NASDAQ:NVCR) announced today that management will participate in three upcoming investor events. 2025 Wells Fargo Healthcare Conference, September 4, 2025: Ashley Cordova, Chief Executive Officer, will take
- 1y agoNVCRNovocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic CancerBusiness WireNovocure (NASDAQ:NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally
- 1y agoNVCRNovoCure Limited (NVCR) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoNVCRNovocure Reports Second Quarter 2025 Financial ResultsBusiness WireQuarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PANOVA-3 clinical trial presented at 2025 ASCO Annual Meeting and ESMO
- 1y agoNVCRNovocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025Business WireTTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated a statistically significant and clinically meaningful benefit across multiple measures of pain and in a post-hoc analysis significantly
- 1y agoNVCRNovocure to Report Second Quarter 2025 Financial ResultsBusiness WireNovocure (NASDAQ:NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT,
- 1y agoNVCRZLABZai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingBusiness WireTTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable,
- 1y agoNVCRResults From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingBusiness WireTTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable,
- 1y agoNVCRNovocure Announces Upcoming Investor EventsBusiness WireNovocure (NASDAQ:NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31 at 8:00 p.m. ET / 7:00
- 1y agoNVCRNovocure Reports First Quarter 2025 Financial ResultsBusiness WireQuarterly net revenues of $155 million, up 12% year-over-year, with 4,268 active patients on therapy as of March 31, 2025 Results from Phase 3 PANOVA-3 trial in pancreatic cancer accepted as late-breaking abstract for
- 1y agoNVCRNovocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual MeetingBusiness WireNovocure (NASDAQ:NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer at the 2025 American Society of